A Phase 1 interventional study of HT-6184 and HT-6184 Placebo in Normal Healthy Subjects, sponsored by Halia Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-28.
Sponsored by Halia Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are to evaluate the safety and tolerability of HT-6184 when administered as single oral doses at escalating dose levels in healthy volunteer subjects.
The secondary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of HT-6184. Results of the PD analyses will be used to determine the minimal biologically effective dose (MBED): the lowest dose that achieves >70% target inhibition compared to unstimulated vehicle controls over 24 hours in 4 of 6 treated volunteers.
This is a phase 1, randomized, placebo-controlled, single-center, single and multiple ascending dose study designed to evaluate the safety, tolerability, PK, and PD of HT-6184.
Each cohort in the study will be comprised of 8 subjects, 6 subjects will receive HT-6184 and 2 subjects will receive placebo. A dose range of 1 mg - 4 mg HT-6184 will be explored in the SAD and MAD escalation cohorts in adult healthy volunteer subjects. Safety and PK data from the 8 completed cohorts will be reviewed.
For the SAD portion subjects will be divided into 4 cohorts of 8 subjects in each cohort. Four (4) ascending single doses (1 dose level per cohort) will be investigated.
Subjects will be screened for eligibility to participate in the study up to 26 days (Day -28) prior to admission to the study center on Day -2. Eligible subjects will be admitted to the study center on Day -2 and will be discharged on Day 2 after all scheduled assessments have been completed. Following discharge, subjects will return to the study center for follow-up visits on Day 7 and receive a follow-up phone call on Day 30.
A modified Fibonacci escalation schedule starting at 1 mg, (escalating by 100%) 2 mg, (escalating by 50%) 3 mg, and (escalating by 33%) 4 mg. The study will have an ongoing assessment of all available safety, tolerability, and concentration data prior to initiation of the next cohort.
For the MAD portion subjects will be divided into 4 cohorts of 8 subjects in each cohort. Four (4) ascending multiple doses (1 dose level per cohort) will be investigated.
Subjects will be screened for eligibility to participate in the study up to 26 days (Day -28) prior to admission to the study center on Day -2. Eligible subjects will be admitted to the study center on Day -2 and will be discharged on Day 13 after all scheduled assessments have been completed. Following discharge, subjects will return to the study center for a follow-up visit on Day 21 and receive a follow-up phone call on Day 42.
Halia Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female partners of male participants of , and female participants of childbearing potential must agree to use a highly effective method of prior to study entry, for the duration of study participation, and a minimum of 30 days after the last dose. Highly effective forms of contraception include the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 - 6 subjects x 1 mg HT-6184 QD on Day 1
Drug: HT-6184
Cohort 1 - 2 subjects x placebo, QD on Day 1
Drug: HT-6184 Placebo
Cohort 2 - 6 subjects x 2 mg HT-6184 QD on Day 1
Drug: HT-6184
Cohort 2 - 2 subjects x placebo, QD on Day 1
Drug: HT-6184 Placebo
Cohort 3 - 6 subjects x 3 mg HT-6184 QD on Day 1
Drug: HT-6184
Cohort 3 - 2 subjects x placebo, QD on Day 1
Drug: HT-6184 Placebo
Cohort 4 - 6 subjects x 4 mg HT-6184 QD on Day 1
Drug: HT-6184
Cohort 4 - 2 subjects x placebo, QD on Day 1
Drug: HT-6184 Placebo
Cohort 5 - 6 subjects x 1 mg HT-6184 QD on Day 1-5, 8-12
Drug: HT-6184
Cohort 5 - 2 subjects x 1 mg placebo, QD on Day 1-5, 8-12
Drug: HT-6184 Placebo
Cohort 6 - 6 subjects x 2 mg HT-6184 QD on Day 1-5, 8-12
Drug: HT-6184
Cohort 6 - 2 subjects x 2 mg placebo, QD on Day 1-5, 8-12
Drug: HT-6184 Placebo
Cohort 7 - 6 subjects x 3 mg HT-6184 QD on Day 1-5, 8-12
Drug: HT-6184
Cohort 7 - 2 subjects x 3 mg placebo, QD on Day 1-5, 8-12
Drug: HT-6184 Placebo
Cohort 8 - 6 subjects x 4 mg HT-6184 QD on Day 1-5, 8-12
Drug: HT-6184
Cohort 8 - 2 subjects x 4 mg placebo, QD on Day 1-5, 8-12
Drug: HT-6184 Placebo
Oral capsule
Oral capsule
Incidence of adverse events administered as single oral doses at escalating dose levels in healthy volunteer subjects.
Safety and tolerability of HT-6184 as measured by subject incidence of treatment-related adverse events.
Time frame: up to 6 weeks
Incidence of abnormal laboratory test results
Safety and tolerability of HT-6184 as measured by subject incidence of treatment-related abnormal lab values.
Time frame: up to 6 weeks
Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)
Safety and tolerability of HT-6184 as measured by subject incidence of treatment-related abnormal ECG.
Time frame: up to 6 weeks
Incidence of treatment-emergent clinically abnormal physical exam
Safety and tolerability of HT-6184 as measured by subject incidence of treatment-related abnormal physical exam.
Time frame: up to 6 weeks
Plasma maximum measured drug concentration (Cmax)
Cmax will be reported.
Time frame: up to 6 weeks
Time of maximum concentration (Tmax)
Tmax will be reported.
Time frame: up to 6 weeks
Area under the plasma concentration-time curve (AUC0-24)
Area under the plasma concentration-time curve from 0 until 24 hours post-dose will be reported.
Time frame: up to 6 weeks
Area under the plasma concentration-time curve (AUC0-last)
Area under the plasma concentration-time curve, from 0 to the last quantifiable timepoint will be reported.
Time frame: up to 6 weeks
Area under the plasma concentration-time curve (AUC0-inf)
Area under the plasma concentration-time curve, from 0 to infinity will be reported.
Time frame: up to 6 weeks
Plasma half-life (T½)
T½ will be reported.
Time frame: up to 6 weeks
Terminal elimination rate constant (kel)
Terminal elimination rate constant will be reported.
Time frame: up to 6 weeks
Apparent clearance (CL/F)
CL/F will be reported.
Time frame: up to 6 weeks
Apparent volume of distribution at steady state (Vss/F)
Vss/F will be reported.
Time frame: up to 6 weeks
Ran from Jun 2022 to primary completion in Jul 2023, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ofirnoflast
Halia Therapeutics, Inc.